Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: from the new website. At least they responded to recent letter.
"At present our focus is the licensing of the MMP Portfolio."

Really? How about "At present we are working diligently to ensure our next quarterly report, to 2/28/14, will be available to shareholders by mid-March. In parallel we have focus on how to take advantage of events relating to our principal partner in a way to secure better terms for our future relationship with him, including equal and balanced rights in our co-marketing agreement and a more reasonable approach to announcements related to that business. We are also aggressively pursuing TPL and Alliacense to obtain unredacted copies of all MMP correspondence between those two parties and any third parties, and in particular companies who have been sent notice of possible infringement of the MMP technology patents. We have also formally notified TPL and Alliacense that not only do we expect them to use best efforts to enforce the MMP patents regardless of their current legal distractions but also to provide a 12 month written plan of what actions they will be taking to increase pressure on possible infringers, including more notifications. Finally, we are planning our next Annual Shareholder Meeting for Carlsbad in early May and will request detailed presentations by Alliacense and James Otteson relevant to current state and future strategy for maximizing income to our company by MMP licensing. We will dedicate 2 hours solely for shareholders to ask, and have answered, questions related to the company and its plans."
Share
New Message
Please login to post a reply